

Can't fill your Lantus prescription? Learn about real alternatives like Basaglar, Toujeo, Tresiba, and generic Insulin Glargine options available in 2026.
Being told your pharmacy doesn't have Lantus in stock can feel like the ground dropping out from under you. For people living with diabetes, insulin isn't optional — it's a daily necessity. If you're having trouble filling your Lantus prescription, there are real alternatives your doctor can prescribe. You don't have to go without.
This guide walks you through what Lantus is, how it works, and the best alternatives available in 2026. For background on why Lantus is hard to find, check out our explainer.
Lantus is a brand-name long-acting insulin manufactured by Sanofi. Its generic name is Insulin Glargine. It's FDA-approved to improve blood sugar control in:
Lantus is available as a 10 mL vial (100 Units/mL) and a prefilled SoloStar pen (3 mL cartridge, 100 Units/mL). It's one of the most widely prescribed basal insulins in the country. To learn more about the drug itself, see our detailed post on what Lantus is and how it's used.
Lantus works by mimicking the body's natural background insulin. After you inject it under the skin, it forms tiny clusters (microprecipitates) that dissolve slowly over approximately 24 hours. This provides a steady, "peakless" level of insulin that helps keep your blood sugar stable between meals and overnight.
For a deeper dive, read our guide on how Lantus works.
Because Lantus is a basal insulin, any alternative needs to provide the same kind of long-lasting background coverage. That's what the options below deliver.
Basaglar is made by Eli Lilly and contains the same active ingredient as Lantus: Insulin Glargine at 100 Units/mL. It's classified as a "follow-on biologic" — essentially the same drug manufactured by a different company.
Key facts about Basaglar:
Switching from Lantus to Basaglar is usually straightforward since it's the same molecule. Your doctor can typically convert you at a 1:1 dose ratio.
Semglee (Insulin Glargine-yfgn) was the first FDA-approved interchangeable biosimilar to Lantus, meaning pharmacies could substitute it without needing a new prescription from your doctor. While Biocon discontinued the Semglee brand in December 2025, generic Insulin Glargine vials and pens from other manufacturers remain available.
Key facts:
Toujeo is also made by Sanofi and contains the same active ingredient — Insulin Glargine — but at a higher concentration: 300 Units/mL instead of 100 Units/mL. This concentrated formulation offers some unique advantages.
Key facts about Toujeo:
If you've been experiencing blood sugar swings or nighttime lows on Lantus, Toujeo might actually be a better fit for you — not just a backup option.
Tresiba is made by Novo Nordisk and contains a completely different insulin molecule: Insulin Degludec. It's an ultra-long-acting insulin with a duration of up to 42 hours, making it the longest-lasting basal insulin available.
Key facts about Tresiba:
Tresiba is an excellent choice for patients who need more dosing flexibility or who experience frequent hypoglycemia on Lantus. However, it requires a new prescription and is a different drug class switch.
If you can't find Lantus, here's how to have a productive conversation with your prescriber:
For help finding a prescriber who can help, see our guide on finding a doctor who prescribes Lantus.
Not being able to fill your Lantus prescription is scary, but you have real options. Basaglar and generic Insulin Glargine are the closest substitutes since they use the same active ingredient. Toujeo and Tresiba are excellent alternatives that might even work better for some patients.
The key is to act quickly — don't wait until you're completely out of insulin to start looking. Use Medfinder to search for available stock, and talk to your doctor about which alternative is right for you. For more on managing costs during a switch, check out our savings guide for Lantus.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.